AMD

When a patient has low contrast sensitivity, it means they have difficulty perceiving and distinguishing objects or patterns with subtle differences in contrast. This can have several implications for their vision and daily life, since our world is not merely black and white.

The agreement redefines participant requirements and a slightly increased daily release of the drug, which is currently in a Phase 3 clinical trial.

A new case-control study found that older people ages 70 and older living in South Korea’s urban areas were at a significantly higher risk for developing incident exudative age-related macular degeneration.

OCU410 is a modifier gene therapy product candidate being developed by Ocugen for dry AMD.

The study of OliX Pharmaceuticals' investigative property saw encouraging results and helped to identify suitable dosing levels for future clinical trials.

The company announced key secondary endpoints were achieved with both EYP-1901 doses. These include a more than 80% reduction in treatment burden, with nearly two-thirds of eyes supplement-free up to 6 months.

Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, OD, FAAO, recap the diverse topics at EyeCon 2023, emphasizing the collaborative spirit between optometrists and ophthalmologists in addressing issues such as myopia management, diabetic eye conditions, cataract surgery, and patient referrals.

A rapid-fire, top-level review of what happened in optometry in 2023.

According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema. The approval is based on two Phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept.

Prevention should be at the forefront of the discussion.

The FDA determined it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.

Clinicians may have difficulty in making a diagnosis.

According to Regeneron, the approval was based on data in the PULSAR and PHOTON trials, in which the drug demonstrated clinically equivalent vision gains to aflibercept Injection 2 mg that were maintained with fewer injections.

According to Regeneron, visual gains and safety of aflibercept 8 mg remained consistent with the established profile of aflibercept 2 mg injection.

The investigators explored the effects of the following covariates on development of AMD: sex, ethnicity, smoking history, fluoxetine use, obesity, diabetes mellitus, and hypertension.

Opthea’s lead biologic drug candidate OPT-302, which is under investigation for the treatment of wet AMD, received nonproprietary drug name sozinibercept, which is a critical step in the FDA approval process.

Jay M. Haynie, OD, FAAO, FORS, caught up with Peg Achenbach, OD, FAAO, while at the 2023 Victoria Conference to share highlights from his presentation on staying current with the AMD landscape.

While these injections are the standard treatment for this patient population, the investigators found a subgroup of patients who had severe visual loss between 2 consecutive intravitreal injections.

Researchers investigated the relationship between visual functioning measured using the National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) and mortality in patients with various stages of AMD.

A recently completed non-human primate study of VGX-0111 demonstrated good tolerability, provided strong transgene expression in the targeted region of the retina, and increased production of the lipids whose decline is associated with macular degeneration.

Mohammad Rafieetary, OD, FAAO, shares brief highlights from his 2023 AOA presentation, "AMD updates: Staying current with its landscape," which he co-presented with Jay Haynie, OD, FAAO.

Over the past decade the progress in retinal disease treatments has exploded with increased numbers of approved pharmaceutical compounds, resulting in more options for treating retinal disease with intravitreal agents and more are in the pipeline.

Jeffry Gerson, OD, FAAO, who presented a poster on the Light Site 3 clinical study at the AOA online e-poster event, discusses a promising new treatment for patients with AMD.

The day helps to bring focus and awareness to risk factors for early vision loss associated with smoking.

The iPredict AI Eye Screening System will provide a fully automated age-related macular degeneration (AMD) screening report in less than 60 seconds.

The two companies have announced an exclusive agreement for Polifarma to commercialize AVT06, the proposed biosimilar to Eylea, in Turkey.

Acceptance is based on two phase 3 studies that demonstrated early and sustained vision improvement, meeting primary endpoint of non-inferiority compared to aflibercept.

Alvin Liu, MD, sat down with Sheryl Stevenson, Group Editorial Director, Ophthalmology Times®, to discuss his presentation on deep learning and 3D OCT at the ASCRS annual meeting in San Diego.

Efavirenz boosts cholesterol turnover in retina, brain.

Tina Mac Donald, OD, shares highlights from her presentation on living with an untreatable eye disease, which she presented during the 2023 Controversies in Modern Eye Care meeting.